{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:27:11Z","timestamp":1786591631100,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10072-026-09211-0","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:17:59Z","timestamp":1783045079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1025-1068","authenticated-orcid":false,"given":"Bara M.","family":"Hammadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeen","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9405-0932","authenticated-orcid":false,"given":"Issam","family":"Abu-Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7960-6222","authenticated-orcid":false,"given":"Mohammed S.","family":"Alhallaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1417-879X","authenticated-orcid":false,"given":"Mustafa","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-0889","authenticated-orcid":false,"given":"Ahmed","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mays","family":"Shawawrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"9211_CR1","unstructured":"Babaesfahani A, Khanna NR, Patel P, Kuns B (2024) Natalizumab"},{"key":"9211_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14764","author":"G Vivekanandan","year":"2021","unstructured":"Vivekanandan G et al (2021) Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.14764","journal-title":"Cureus"},{"issue":"3","key":"9211_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/fvl.10.12","volume":"5","author":"AS Sariba\u015f","year":"2010","unstructured":"Sariba\u015f AS, \u00d6zdemir A, Lam C, Safak M (2010) Jc virus-induced progressive multifocal leukoencephalopathy. Future Virol 5(3):313\u2013323. https:\/\/doi.org\/10.2217\/fvl.10.12","journal-title":"Future Virol"},{"key":"9211_CR4","doi-asserted-by":"publisher","unstructured":"Zhovtis Ryerson L et al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(8):885\u2013889. https:\/\/doi.org\/10.1136\/jnnp-2015-312940","DOI":"10.1136\/jnnp-2015-312940"},{"issue":"2","key":"9211_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13760-024-02480-6","volume":"124","author":"EM Rabea","year":"2024","unstructured":"Rabea EM et al (2024) Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurol Belg 124(2):407\u2013417. https:\/\/doi.org\/10.1007\/s13760-024-02480-6","journal-title":"Acta Neurol Belg"},{"key":"9211_CR6","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71\u2013n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"9211_CR7","doi-asserted-by":"publisher","unstructured":"Higgins JPT et al (eds) (2019) Cochrane handbook for systematic reviews of interventions. Wiley. https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"issue":"5","key":"9211_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","volume":"7","author":"R Bomprezzi","year":"2014","unstructured":"Bomprezzi R, Pawate S (2014) Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 7(5):227\u2013231. https:\/\/doi.org\/10.1177\/1756285614540224","journal-title":"Ther Adv Neurol Disord"},{"key":"9211_CR9","doi-asserted-by":"publisher","unstructured":"Butzkueven H et al (2021) No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score\u2013matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Ther Adv Neurol Disord 14. https:\/\/doi.org\/10.1177\/17562864211042458","DOI":"10.1177\/17562864211042458"},{"issue":"3","key":"9211_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcph.1737","volume":"61","author":"I Chang","year":"2021","unstructured":"Chang I, Muralidharan KK, Campbell N, Ho P (2021) Modeling the efficacy of natalizumab in multiple sclerosis patients who switch from every-4\u2010week dosing to extended\u2010interval dosing. J Clin Pharmacol 61(3):339\u2013348. https:\/\/doi.org\/10.1002\/jcph.1737","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"9211_CR11","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","volume":"91","author":"CG Chisari","year":"2020","unstructured":"Chisari CG et al (2020) Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 91(12):1297\u20131303. https:\/\/doi.org\/10.1136\/jnnp-2020-323472","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"9211_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","volume":"17","author":"M Clerico","year":"2020","unstructured":"Clerico M et al (2020) Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics 17(1):200\u2013207. https:\/\/doi.org\/10.1007\/s13311-019-00776-7","journal-title":"Neurotherapeutics"},{"key":"9211_CR13","doi-asserted-by":"publisher","unstructured":"Foley JF et al (2024) Pharmacokinetics and pharmacodynamics of natalizumab 6-week dosing vs continued 4-week dosing for relapsing-remitting multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 11(6). https:\/\/doi.org\/10.1212\/NXI.0000000000200321","DOI":"10.1212\/NXI.0000000000200321"},{"key":"9211_CR14","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Est\u00e9vez DA, P\u00e9rez-Lorenzo G, Fern\u00e1ndez-P\u00e9rez MJ, Cid-Rodr\u00edguez C, Ozaita-Arteche G (2022) Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis. Rev Neurol 74(8). https:\/\/doi.org\/10.33588\/rn.7408.2021311","DOI":"10.33588\/rn.7408.2021311"},{"key":"9211_CR15","doi-asserted-by":"publisher","first-page":"120689","DOI":"10.1016\/j.jns.2023.120689","volume":"450","author":"L Jeantin","year":"2023","unstructured":"Jeantin L et al (2023) Natalizumab extended-interval dosing in a real-life setting. J Neurol Sci 450:120689. https:\/\/doi.org\/10.1016\/j.jns.2023.120689","journal-title":"J Neurol Sci"},{"issue":"13","key":"9211_CR16","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1177\/13524585221108080","volume":"28","author":"M Johnsson","year":"2022","unstructured":"Johnsson M et al (2022) No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Multiple Scler J 28(13):2070\u20132080. https:\/\/doi.org\/10.1177\/13524585221108080","journal-title":"Multiple Scler J"},{"key":"9211_CR17","doi-asserted-by":"publisher","unstructured":"van Kempen ZLE et al (2020) Personalized extended interval dosing of natalizumab in MS. Neurology 95(6). https:\/\/doi.org\/10.1212\/WNL.0000000000009995","DOI":"10.1212\/WNL.0000000000009995"},{"key":"9211_CR18","doi-asserted-by":"publisher","first-page":"106146","DOI":"10.1016\/j.msard.2024.106146","volume":"92","author":"G Leodori","year":"2024","unstructured":"Leodori G et al (2024) Improvement of fatigue, depression, and processing speed two weeks post natalizumab infusion in multiple sclerosis: no difference between standard and extended interval dosing schedules. Mult Scler Relat Disord 92:106146. https:\/\/doi.org\/10.1016\/j.msard.2024.106146","journal-title":"Mult Scler Relat Disord"},{"key":"9211_CR19","doi-asserted-by":"publisher","first-page":"117385","DOI":"10.1016\/j.jns.2021.117385","volume":"424","author":"SF De Mercanti","year":"2021","unstructured":"De Mercanti SF et al (2021) MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci 424:117385. https:\/\/doi.org\/10.1016\/j.jns.2021.117385","journal-title":"J Neurol Sci"},{"issue":"2","key":"9211_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","volume":"12","author":"J Pelle","year":"2023","unstructured":"Pelle J et al (2023) Real-world effectiveness of natalizumab extended interval dosing in a french cohort. Neurol Ther 12(2):529\u2013542. https:\/\/doi.org\/10.1007\/s40120-023-00440-5","journal-title":"Neurol Ther"},{"issue":"1","key":"9211_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14735\/amcsnn202079","volume":"83\/116","author":"M Petr\u017ealka","year":"2020","unstructured":"Petr\u017ealka M et al (2020) Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients. \u010cesk\u00e1 slovensk\u00e1 neurologie neurochirurgie 83\/116(1):79\u201383. https:\/\/doi.org\/10.14735\/amcsnn202079","journal-title":"\u010cesk\u00e1 slovensk\u00e1 neurologie neurochirurgie"},{"key":"9211_CR22","doi-asserted-by":"publisher","unstructured":"Riancho J et al (2021) Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.614715","DOI":"10.3389\/fimmu.2021.614715"},{"issue":"3","key":"9211_CR23","doi-asserted-by":"publisher","first-page":"e00338","DOI":"10.1016\/j.neurot.2024.e00338","volume":"21","author":"S Ruggieri","year":"2024","unstructured":"Ruggieri S et al (2024) Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience. Neurotherapeutics 21(3):e00338\u2013e. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00338","journal-title":"Neurotherapeutics"},{"key":"9211_CR24","doi-asserted-by":"publisher","unstructured":"Ryerson LZ et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93(15). https:\/\/doi.org\/10.1212\/WNL.0000000000008243","DOI":"10.1212\/WNL.0000000000008243"},{"key":"9211_CR25","doi-asserted-by":"publisher","first-page":"103480","DOI":"10.1016\/j.msard.2021.103480","volume":"58","author":"LZ Ryerson","year":"2022","unstructured":"Ryerson LZ et al (2022) No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS. Mult Scler Relat Disord 58:103480. https:\/\/doi.org\/10.1016\/j.msard.2021.103480","journal-title":"Mult Scler Relat Disord"},{"key":"9211_CR26","doi-asserted-by":"publisher","first-page":"104561","DOI":"10.1016\/j.msard.2023.104561","volume":"72","author":"LZ Ryerson","year":"2023","unstructured":"Ryerson LZ et al (2023) Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 72:104561. https:\/\/doi.org\/10.1016\/j.msard.2023.104561","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"9211_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/13524585231225855","volume":"30","author":"AA Toorop","year":"2024","unstructured":"Toorop AA et al (2024) Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis. Multiple Scler J 30(2):266\u2013271. https:\/\/doi.org\/10.1177\/13524585231225855","journal-title":"Multiple Scler J"},{"issue":"14","key":"9211_CR28","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M et al (2021) A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis. Multiple Scler J 27(14):2240\u20132253. https:\/\/doi.org\/10.1177\/13524585211003020","journal-title":"Multiple Scler J"},{"key":"9211_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","volume":"24","author":"BI Yamout","year":"2018","unstructured":"Yamout BI et al (2018) Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 24:113\u2013116. https:\/\/doi.org\/10.1016\/j.msard.2018.06.015","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"9211_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF et al (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21(7):608\u2013619. https:\/\/doi.org\/10.1016\/S1474-4422(22)00143-0","journal-title":"Lancet Neurol"},{"key":"9211_CR31","doi-asserted-by":"publisher","first-page":"jnnp","DOI":"10.1136\/jnnp-2023-332119","volume":"332119","author":"AA Toorop","year":"2023","unstructured":"Toorop AA et al (2023) Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry 332119:jnnp. https:\/\/doi.org\/10.1136\/jnnp-2023-332119","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9211_CR32","doi-asserted-by":"publisher","unstructured":"Sefero\u011flu M et al (2025) Comparative efficacy and safety of extended versus standard interval dosing of natalizumab in relapsing\u2013remitting multiple sclerosis patients: a multicenter analysis. CNS Neurosci Ther 31(5). https:\/\/doi.org\/10.1111\/cns.70445","DOI":"10.1111\/cns.70445"},{"key":"9211_CR33","doi-asserted-by":"publisher","first-page":"105334","DOI":"10.1016\/j.msard.2023.105334","volume":"80","author":"T Mousavi","year":"2023","unstructured":"Mousavi T, Fatemi B, Nikfar S, Sahraian MA (2023) Is there any benefit in extended-interval dosing regimen of natalizumab for patients with relapsing-remitting multiple sclerosis? results from a systematic review and meta-analysis. Mult Scler Relat Disord 80:105334. https:\/\/doi.org\/10.1016\/j.msard.2023.105334","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"9211_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.nrl.2021.10.005","volume":"37","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar L et al (2022) Gadolinium-enhanced brain lesions in multiple sclerosis relapse. Neurolog\u00eda 37(7):557\u2013563. https:\/\/doi.org\/10.1016\/j.nrl.2021.10.005","journal-title":"Neurolog\u00eda"},{"issue":"2","key":"9211_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0022-510X(99)00054-4","volume":"164","author":"M Rovaris","year":"1999","unstructured":"Rovaris M, Mastronardo G, Prandini F, Bastianello S, Comi G, Filippi M (1999) Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. J Neurol Sci 164(2):148\u2013152. https:\/\/doi.org\/10.1016\/S0022-510X(99)00054-4","journal-title":"J Neurol Sci"},{"issue":"3","key":"9211_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/acn3.51130","volume":"8","author":"B Tugemann","year":"2021","unstructured":"Tugemann B, Berger JR (2021) Improving risk-stratification of natalizumab\u2010associated PML. Ann Clin Transl Neurol 8(3):696\u2013703. https:\/\/doi.org\/10.1002\/acn3.51130","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"9211_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-023-01383-4","volume":"47","author":"LV Rindi","year":"2024","unstructured":"Rindi LV et al (2024) Drug-induced progressive multifocal leukoencephalopathy (PML): a systematic review and meta-analysis. Drug Saf 47(4):333\u2013354. https:\/\/doi.org\/10.1007\/s40264-023-01383-4","journal-title":"Drug Saf"},{"key":"9211_CR38","doi-asserted-by":"publisher","unstructured":"Guger M et al (2025) De-escalation treatment strategies from natalizumab in patients with relapsing multiple sclerosis in Austria. Eur J Neurol 32(7). https:\/\/doi.org\/10.1111\/ene.70282","DOI":"10.1111\/ene.70282"},{"issue":"6","key":"9211_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","volume":"39","author":"BAC Cree","year":"2025","unstructured":"Cree BAC, Berger JR, Greenberg B (2025) The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function. CNS Drugs 39(6):545\u2013564. https:\/\/doi.org\/10.1007\/s40263-025-01182-8","journal-title":"CNS Drugs"},{"key":"9211_CR40","doi-asserted-by":"publisher","unstructured":"Yang J, Chun K (2023) Serum natalizumab and anti-natalizumab antibody concentrations may be useful in patient management (P1-3.002). Neurology 100(17:S2) https:\/\/doi.org\/10.1212\/WNL.0000000000204266","DOI":"10.1212\/WNL.0000000000204266"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09211-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:41:52Z","timestamp":1786588912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09211-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9211"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09211-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Owing to the nature of this research design involving the synthesis of existing data, it is exempt from review by the Institutional Review Board (IRB). As a result, no ethical approval was required for this article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published randomized clinical trials. No individual patient data or identifiable information was used.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"602"}}